On November 11, 2024, Fred Grossman, the Chief Medical Officer of Coya Therapeutics Inc (COYA, Financial), acquired 2,710 shares of the company. This transaction was documented in an SEC Filing. Following this acquisition, the insider now directly holds a total of 2,710 shares of Coya Therapeutics Inc.
Coya Therapeutics Inc is engaged in the development of therapies aimed at modulating the immune system to treat diseases with unmet medical needs. The company's approach includes leveraging regulatory T cells and related mechanisms.
The shares were purchased at a price of $7.37 each, valuing the transaction at approximately $19,972.70. On the day of the purchase, the market cap of Coya Therapeutics Inc was reported to be $121.13 million.
Over the past year, the insider transaction history at Coya Therapeutics Inc shows a trend of more insider buying than selling. There have been 2 insider buys and 0 insider sells. The insider, Fred Grossman, has been active in the market, with a total of 2,710 shares purchased and 0 shares sold.
This insider buying activity could be of interest to investors and analysts who track insider behaviors as indicators of confidence and potential future performance of the company.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, interested parties are encouraged to visit the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
